GSK’s Arexvy Vaccine Receives the MHLW’s Approval for its Expanded Age Indication to Prevent RSV Disease
Shots:
- The Japanese MHLW has granted approval to GSK's Arexvy RSV vaccine for adults aged 50-59 years at increased risk, expanding its use beyond those aged ≥60 years
- The approval was based on a global P-III trial, which included 4 Japanese sites, showing non-inferior immunogenicity in adults 50-59 years of age who at increased risk of RSV. Safety & reactogenicity aligned with the P-III study data involving adults ≥60 years of age
- The vaccine has been approved across 35 regions, incl. the US, for the same population with the recent EC’s nod in Aug 2024
Ref: GSK Image:GSK
Related News:- GSK’s Arexvy Vaccine Receives the EC’s Approval for its Expanded Age Indication to Prevent Lower Respiratory Tract Disease (LRTD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
